Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study
Table 1
Baseline characteristics and pulmonary hemodynamics by RHC.
Variable
PPH group (n = 23)
RPH group (n = 35)
Demographics
Male, n (%)
16 (69.57)
23 (65.71)
0.783
Female, n (%)
7 (30.43)
12 (34.29)
0.684
Age (years)
69.78 ± 10.22
70.60 ± 11.14
0.891
Medical history
Coronary artery disease (%)
9 (39.13)
13 (37.14)
0.965
Hypertensive heart disease (%)
2 (8.70)
3 (8.57)
0.974
Coronary heart disease with hypertension (%)
7 (30.43)
10 (28.57)
0.862
Dilated cardiomyopathy (%)
2 (8.69)
3 (8.57)
0.975
Degenerative valvular heart disease (%)
3 (13.04)
6 (17.14)
0.763
Course of disease (years)
3.09 ± 2.22
3.69 ± 2.64
0.012
Medication, n (%)
Diuretics
22 (95.65)
33 (94.29)
0.912
Hydrochlorothiazide 25 mg qd
15
24
Torasemide 20 mg qd
7
9
Antisterone
22
31
Nitrates
17 (73.91)
26 (74.29)
0.893
ACEI/ARB
19 (82.61)
29 (82.86)
0.981
β-Blockers
20 (86.96)
28 (80.00)
0.261
Pulmonary hemodynamics
PASP (mmHg)
47.17 ± 8.47
62.9 ± 17.47
0.003
mPAP (mmHg)
33.82 ± 7.26
45.26 ± 14.96
0.007
PAWP (mmHg)
23.26 ± 5.26
23.14 ± 5.26
0.947
TPG (mmHg)
10.08 ± 1.88
22.11 ± 2.25
0.000
PVR (WU)
2.15 ± 0.88
5.24 ± 2.55
0.003
CO (L/min)
4.84 ± 1.56
4.19 ± 1.26
0.000
Cardiac function (n/n)
NYHA I-II/III-IV
5/18
8/27
0.9426
Data are presented as number and rate or mean ± standard deviation; Student’s t-test was used for continuous normally distributed variables; the Wilcoxon test was used for continuous nonnormally distributed variables; ranked data were tested by rank sum test; PASP, pulmonary artery systolic pressure; mPAP, mean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; TPG, transpulmonary pressure gradient; PVR, pulmonary vascular resistance; CO, cardiac output; NYHA, New York Heart Association; the change from baseline, .
